{"schema_version":"secwatch.filing_event.v1","accession":"0001725160-25-000147","form_type":"8-K","ticker":"ZNTL","cik":"0001725160","company_name":"Zentalis Pharmaceuticals, Inc.","filed_at":"2025-08-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.807296+00:00","generated_at":"2026-05-17T19:39:23.538110+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Zentalis reports Q2 2025 cash of $303.4M; DENALI Phase 2 on track for topline by end 2026","bullets":["Cash, cash equivalents and marketable securities $303.4M as of June 30, 2025; runway extended into late 2027.","R&D expenses fell to $27.6M from $48.4M YoY; G&A expenses fell to $8.4M from $16.7M YoY.","DENALI Phase 2 trial of azenosertib in Cyclin E1-positive PROC remains on track; topline data expected by year-end 2026.","Strategic restructuring completed; no further non-recurring expenses expected.","Part 2 data, if successful, could support accelerated approval subject to FDA feedback."],"urls":{"canonical":"https://secwatch.observer/filing/0001725160-25-000147","json":"https://secwatch.observer/filing/0001725160-25-000147.json","markdown":"https://secwatch.observer/filing/0001725160-25-000147.md","text":"https://secwatch.observer/filing/0001725160-25-000147.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1725160/000172516025000147/0001725160-25-000147-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1725160/000172516025000147/zntl-20250806.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T19:39:23.538110+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}